Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-06
2007-03-06
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S006900, C514S008100, C514S019300, C530S300000, C530S331000, C530S332000
Reexamination Certificate
active
10472252
ABSTRACT:
The present invention provides a method of treatment and/or prophylaxis of arthritis in a vertebrate comprising administering to said vertebrate in need of said treatment and/or prophylaxis a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, optionally together with a pharmaceutically acceptable carrier, diluent or excipient, wherein said compound of formula (I) is defined as: A—(L—Y)p, wherein: A comprises at least one substantially cell-membrane impermeable pendant group; L comprises any suitable linker and/or spacer group; Y comprises at least one arsenoxide or arsenoxide equivalent; p is an integer from 1 to 10; and the sum total of carbon atoms in A and L together, is greater than 6.
REFERENCES:
patent: 3883659 (1975-05-01), Friedheim et al.
patent: 2 781 674 (1998-07-01), None
patent: WO 98/51297 (1998-11-01), None
patent: WO 99/18798 (1999-04-01), None
patent: WO 99/55344 (1999-11-01), None
patent: WO 00/56742 (2000-09-01), None
patent: WO 01/21628 (2001-03-01), None
patent: WO 03/003011 (2003-01-01), None
patent: WO 03/039564 (2003-05-01), None
PM Loiseau, et al. Antimicrob. Agents Chemo. (2000) 44(11), pp. 2954-2961.
“What Causes Arthritis?”, The Arthritis Health Center, Pfizer for Women, http://pfizerforwomen.com/hc—arthritis—02.asp?arthritis Accessed Aug. 11, 2005, 1 page.
“Top 10 Questions”, The Arthritis Foundation. http://www.arthritis.org/resources/arthritisanswers/questions.asp Accessed Aug. 11, 2005, 3 pages.
D.E. Smilek, et al. Proc. Natl. Acad. Sci. USA (1991) 88, pp. 9633-9637.
D. Voet and J.G. Voet. Biochemistry, 2nd Edition.(1995), pp. 235-241.
J. Rudinger. In: Peptide Hormones, JA Parsons, Ed. (1976) 1-7.
A.E. Koch. Ann. Rheum. Dis. (2000) 59(Suppl 1), pp. 165-171.
Fairlamb, Alan H., et al., “Trypanothione is the Primary Target for Arsenical Drugs Against African Trypanosomes,”PNAS, vol. 86 (1989) pp. 2607-2611.
Fairlamb, Alan H. & Cerami, Anthony, “Metabolism and Functions of Trypanothione in the Kinetoplastida,”Ann. Rev. Microbiol., vol. 46 (1992) pp. 695-729.
Cunningham, Mark L., et al., “Mechanism of inhibition of Trypanothione Reductase and Glutathione Reductase by Trivalent Organic Arsenicals,”FEBS, vol. 221 (1994) pp. 285-295.
Bhargava, Kuldeep K., et al., “Effect of Arsenical Drugs on Glutathione Metabolism ofLitomosoides carinii,” Molecular and Biochemical Parasitology, vol. 9 (1983) pp. 29-35.
Carter, Nicola S. & Fairlamb, Alan H., “Arsenical-Resistant Trypanosomes Lack an Unusual Adenosine Transporter,”Nature, vol. 361 (1993) pp. 173-176.
Pisciotto, Patricia T. & Graziano, Joseph H., “Induction of Mucosal Glutathione Synthesis by Arsenic,”Biochemical et Biophysica Acta, vol. 628 (1980) pp. 241-243.
Lawrence, David A., et al., “Surface Thiols of Human Lymphocytes and Their Changes after In Vitro and In Vivo Activation,”Journal of Leukocyte Biology, vol. 60, (1996) pp. 611-618.
Ryser, Hugues J.-P., et al., “Cell Surface Sulfhydryls are Required for the Cytotoxicity of Diphtheria Toxin but not of Ricin in Chinese Hamster Ovary Cells,”Journal of Biological Chemistry, vol. 266, No. 28 (1991) pp. 18439-18442.
Mandel, Richard, et al., “Inhibition of a Reductive function of the Plasma Membrane by Bacitracin and Antibodies Against Protein Disulfide-Isomerase,”PNAS, vol. 90 (1993) pp. 4112-4116.
Couët, Jacques, et al., “Cell Surface Protein Disulfide-Isomerase is Involved in the Shedding of Human Thyotropin Receptor Ectodomain,”Biochemistry, vol. 35 (1996) pp. 14800-14805.
Krishna Rao, A., S. M. & Hausman, R. E., “cDNA for R-Cognin: Homology with a Multifunctional Protein,”PNAS, vol. 90 (1993) pp. 2950-2954.
Zai, Adrian, et al., “Cell-Surface Protein Disulfide Isomerase Catalyzes Transnitrosation and Regulates Intracellular Transfer of Nitric Oxide”The Journal of Clinical Investigation, vol. 103, No. 3 (1999) pp. 393-399.
Essex, David W., et al., “Localization of Protein Disulfide Isomerase to the External Surface of the Platelet Plasma Membrane,”Blood, vol. 85, No. 6 (1995) pp. 2168-2173.
Essex, David W., et al., “Protein Disulphide Isomerase Mediates Platelet Aggregation and Secretion,”British Journal of Haematology, vol. 104 (1999) pp. 448-454.
Täger, Michael, et al., “Membrane-Bound Proteinsulfide Isomerase (PDI) is Involved in Regulation of Surface Expression of Thiols and Drug Sensitivity B-CLL Cells,”Experimental Hematology, vol. 25 (1997) pp. 601-607.
Stathakis, Paul, et al., “Generation of Angiostatin by Reduction and Proteolysis of Plasmin: Catalysis by a Plasmin Reductase Secreted by Cultured Cells,”J. Bio. Chem., vol. 272, No. 33 (1997) pp. 20641-20645.
Stathakis, Paul, et al., “Angiostatin Formation Involves Disulfide Bond Reduction and Proteolysis in Kringle 5 of Plasmin,”J. Biol. Chem., vol. 274, No. 13 (1999) pp. 8910-8916.
Bannai, Shiro & Tsukeda, Hohko, “The Export of Glutathione from Human Diploid Cells in Culture,”J. Bio. Chem., vol. 254, No. 9 (1979) pp. 3444-3450.
Holmgren, Arne, “Thioredoxin and Glutaredoxin Systems,”J. Bio. Chem., vol. 264, No. 24 (1989) pp. 13963-13966.
Rosén, Anders, et al., “A CD4+T Cell Line-Secreted Factor, Growth, Promoting for Normal and Leukemic B Cells, Identified as Thioredoxin,”International Immunology, vol. 7, No. 4 (1995) pp. 625-633.
Happersberger, Peter H., & Glocker, Michael O., “A Mass Spectrometric Approach to the Characterization of Protein Folding Reactions,”Eur. Mass Spectrom, vol. 4 (1998) pp. 209-214.
Halestrap, Andrew P., et al., “The Permeability Transition Pore Complex: Another View,”Biochimie, vol. 84 (2002) pp. 153-166.
Desagher, Solange & Martinou, Jean-Claude, “Mitochondria as the Central Control Point of Apoptosis,”Trends in Cell Biology, vol. 10 (2000) pp. 369-377.
Fantin, Valeria R., et al., “A Novel Mitochondriotoxic Small Molecule that Selectively Inhibits Tumor Cell Growth,”Cancer Cell, vol. 2 (2002) pp. 29-42.
Belzacq, Anne-Sophie, et al., “The Adenine Nucleotide Translocator in Apoptosis,”Biochimie, vol. 84 (2002) pp. 167-176.
McStay, Gavin P ., et al., “Role of Critical Thiol Groups on the Matrix Surface of the Adenine Nucleotide Translocase in the Mechanism of the Mitochondrial Permeability Transition Pore,”Biochem. J., vol. 367 (2002) pp. 541-548.
Koch, Alisa Erika, “The Role of Angiogensis in Rheumatoid Arthritis: Recent Developments,”Ann. Rheum. Dis., vol. 59 (2000) pp. 65-71.
Hayes, Andrew J., “Angioneogenesis in Rheumatoid Arthritis,”The Lancet, vol. 354 (1999) pp. 423-424.
Anonymous, “Arthritis: The Aging Populations of Developed Countries are Likely to present a Growing market for Arthritis Therapies,”Nature Biotechnology, vol. 18 (2000) pp. IT12-IT14.
Ades, Edwin W., et al., “HMEC-1: Establishment of an Immortalized Human Microvascular Endothelial Cell Line,”The Journal of Investigative Dermatology, vol. 99, No. 6 (1992) pp. 683-690.
Andree, Harry A. M., et al., “Binding of Vascular Anticoagulant α (VACα) to Planar Phospholipid Bilayers,”J. Bio. Chem., vol. 265, No. 9 (1990) pp. 4923-4926.
Blankenberg, F.G. & Strauss, H. W., “Will Imaging of Apoptosis Play a Role in clinical Care? A tale of Mice and Men,”Apoptosis, vol. 6 (2001) pp. 117-123.
Dahmoun, M., et al., “Apoptosis, Proliferation and Sex Hormone Receptors in Superficial Parts of Human Endometrium at the End of the Secretory Phase,”The Journal of Clinical Endocrinology&Metabolism, vol. 84, No. 5 (1999) pp. 1737-1743.
Daly, John M., et al., “Neu Differentiation Factor Induces ErbB2 Down-Regulation and Apoptosis of ErbB2-Overexpressing Breast Tumor Cells,”Canc
Kosar Andrew D.
McDonnell Boehnen & Hulbert & Berghoff LLP
New South Innovations Pty Limited
Tsang Cecilia J.
LandOfFree
Treatment of arthritis with arsenoxide compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of arthritis with arsenoxide compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of arthritis with arsenoxide compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3734701